SMARTSOURCING™ Continues To Push AMRI Forward
By Ed Miseta, chief editor, Outsourced Pharma and Clinical Leader
Going into 2012, some analysts wondered about the future of CRO/CMO Albany Molecular Research, Inc. (AMRI). This despite the company’s 22-year track record of success in the industry. Sales were down, margins were tight, the stock price bottomed out at just over $2/share, and questions surrounded the company’s launch of SMARTSOURCING™, its new customer service platform designed to streamline drug development and get products to commercialization faster. One year later, AMRI hopes to put any questions about its future to rest.